Status:
RECRUITING
Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)
Lead Sponsor:
General Hospital of Shenyang Military Region
Conditions:
Overt Hepatic Encephalopathy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Hepatic encephalopathy (HE), a severe complication of decompensated cirrhosis, is characterized as neurocognitive dysfunction. Emerging evidence suggests the potential role of human albumin infusion f...
Detailed Description
Overall, 174 patients with a diagnosis of liver cirrhosis, overt HE, and a serum albumin level of 23-30g/L will be enrolled. They will be stratified according to the severity of overt HE and randomly ...
Eligibility Criteria
Inclusion
- A definite diagnosis of liver cirrhosis and overt HE
- A serum albumin level of 23-30g/L
- Age ≥18 years old
- Sign the informed consent
Exclusion
- Contraindications to human albumin infusion
- A history of transjugular intrahepatic portosystemic shunt
- A diagnosis of acute liver failure
- Severe heart and/or lung diseases
- Psychiatric or nervous diseases
- Pregnant or lactating
Key Trial Info
Start Date :
June 24 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2027
Estimated Enrollment :
174 Patients enrolled
Trial Details
Trial ID
NCT06483737
Start Date
June 24 2025
End Date
June 30 2027
Last Update
August 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Gastroenterology, General Hospital of Northern Theater Command (formerly called General Hospital of Shenyang Military Area)
Shenyang, Liaoning, China